Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nasdaq Biotechnology Ishares ETF
(NQ:
IBB
)
147.87
-0.01 (-0.01%)
Official Closing Price
Updated: 4:15 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Nasdaq Biotechnology Ishares ETF
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
January 30, 2023
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.
Via
Talk Markets
What Are The Equities Market’s Warning Signs?
January 30, 2023
The 52-week New High / New Low ratio for the Nasdaq Composite has actually begun to deteriorate, a clear Risk-Off indication for the short term.
Via
Talk Markets
Inflation, What Inflation?
January 29, 2023
We typically have a song or two in our heads. After all, watching ticks is musical and has a lot of different beats. And typically, those songs turn into parodies.
Via
Talk Markets
Global Stocks: Breaking Out?
January 28, 2023
The S&P 500 is attempting to clear what has been an insurmountable trendline dating back to January 2022.
Via
Talk Markets
The 3 Best Biotech Stocks Under $1 to Buy for January
January 26, 2023
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.
Via
InvestorPlace
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
January 06, 2023
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.
Via
Benzinga
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
January 06, 2023
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to
Via
Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
Small Caps Vs Large Caps: Who Is Leading?
December 07, 2022
Clearly, large-cap stocks have been leading with the Dow Jones down the last year to date, but even though the selling pressure has been constant, trading volume has been anemic.
Via
Talk Markets
Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades'
December 05, 2022
The iShares Biotechnology ETF (NASDAQ: IBB), which includes several large cap biotechs, has recently narrowed its year-to-date loss to aroun
Via
Benzinga
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 02, 2022
By Faith Ashmore, Benzinga
Via
News Direct
Exposures
Product Safety
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 01, 2022
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption.
Via
Benzinga
Will The Dow Jones Continue Higher? Will The Nasdaq Follow?
November 29, 2022
It's been a volatile few weeks in the markets, and it can be hard to tell if we're currently in a risk-on or risk-off environment.
Via
Talk Markets
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
November 28, 2022
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.
Via
Talk Markets
Market Currents: Why Pick Stocks?
November 28, 2022
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...
Via
Talk Markets
Look Who’s Leading Now
November 01, 2022
All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow.
Via
Talk Markets
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
October 31, 2022
Via
Talk Markets
October Was Not So Scary After All - Things To Keep A Watch Out For
October 31, 2022
Via
Talk Markets
These 4 ETFs Feature on CNBC's 'Final Trades'
October 27, 2022
On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq
Via
Benzinga
Russell 2000: How Money Is Made And Lost In Small Caps
October 19, 2022
IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength.
Via
Talk Markets
The Four Indices: Where Each Are In A 4-Year Cycle
October 19, 2022
In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger...
Via
Talk Markets
Steady As She Goes With Healthcare Stocks
October 17, 2022
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.
Via
Talk Markets
Precarious Action In The Bonds And Stock Market
October 16, 2022
Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh?
Via
Talk Markets
Taking The Temperature Of The Major Sector ETFs
October 12, 2022
One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness.
Via
Talk Markets
3 Technical Lessons On Whether Or Not Semiconductors Bottomed
October 03, 2022
The semis ETF SMH has three interesting technical features that are a reliable way to assess what to do from here and how to know if this rally will last.
Via
Talk Markets
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.